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Abstract
Previous studies have identified multiple loci for inherited susceptibility to glioma develop-
ment, including the regulator of telomere elongation helicase 1 (RTEL1). However, the asso-
ciation between RTEL1 variants and risk of glioma has not been well understood. Therefore,
we sought to comprehensively examine the genetic interaction between RTEL1 variants
and risk of glioma with respect to defined histological and molecular subtypes. We employed
a case-control study involving 250 adult glioma patients with previous molecular alterations
and 375 population–based controls within Korean populations. Statistical analyses on the
association between RTEL1 single nucleotide polymorphisms (SNPs) and glioma risk were
conducted using unconditional logistic regression. Additional conditional and stepwise anal-
yses were performed on significant RTEL1 SNPs. We detected significant associations
(Bonferroni P < .05) between six SNPs (rs6089953, rs3848669, rs6010620, rs3787089,
rs6062302, and rs115303435) and risk of glioma in the Korean subjects. The two coding
variants, rs6062302 (D664D) and rs115303435 (A1059T), were plausibly causal variants
and were independent among the significantly associated RTEL1 variants. The glioma sub-
group analyses showed that the causal variants (rs6062302 and rs115303435) may be
associated with increased risk of glioma regardless of histological grades and molecular
alterations. This study provides a deeper understanding of relationships between RTEL1
variants and risk of glioma. Further studies are required to ascertain the impact of those vari-
ants on glioma susceptibility.
Introduction
Glioma is a common tumor which develops within the central nervous system (CNS) [1, 2]. It
is derived from of the neuroglial stem and progenitor cells, accounting for 28% of all brain
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primary tumors and 80% of malignant brain tumors [2]. With the implementation of 2016
World Health Organization Classification of Tumors of the CNS (2016 CNS WHO), the glio-
mas of the brain are required to be diagnosed with the isocitrate dehydrogenase (IDH) and the
chromosome abnormalities of 1p and 19q status [3]. These genetic alterations have been
accepted by worldwide neuro-oncology groups, and most of the glioma patients are being clas-
sified into the category of diffuse astrocytoma, anaplastic astrocytoma, oligodendroglioma,
anaplastic oligodendroglioma, or glioblastoma (GBM) with the molecular signatures [3–5].
In addition to the integrated phenotypic and genotypic features of glioma, many genetic
studies have found that common inherited variants near several genes (TERC, TERT, EGFR,
CDKN2B, PHLDB1 and RTEL1) are associated with increased risk of adult glioma [6].
Genome-wide association studies (GWASs) have found that variants in the regulator of the
telomere elongation helicase1 (RTEL1) gene are associated with increased risk of adult glioma
in White populations [7–9]. In case-control studies for glioma, the associations were detected
for the intronic SNPs (rs6010620 and rs2297440) of RTEL1 in the United States (US) [10] and
Han Chinese populations [11]. Meta-analyses showed that rs6010620 is associated with
increased risk of glioma in populations of both European and Asian descent, although this
SNP has an inconclusive effect on glioma risk [12, 13]. In molecular groups of gliomas that
have gained the telomerase reverse transcriptase (TERT) promoter mutation, IDH mutation,
and 1p/19q codeletion, rs6010620 serves as protection against glioma susceptibility in TERT
mutation status [14].
However, association between RTEL1 SNPs, including coding variants, and risk of gliomas
is not obvious. Therefore, we analyzed the selected RTEL1 SNPs, including previous glioma
variants, for association with risk of adult gliomas in Korean populations. We also examined
the possible interactions between susceptibility alleles and glioma subgroups such as grades,
histologic features, and molecular information.
Materials and methods
Study subjects
The blood samples of 250 Korean glioma patients were collected at the Yonsei University Sev-
erance Hospital and collaborating hospitals, diagnosed between 2006 and 2016. Case subjects
were older than 18 years of age and were categorized into glioma subtypes based on histopath-
ological and molecular features according to the 2007 and 2016 WHO classification of CNS
tumors [3]. For molecular alterations, IDH1 or IDH2 mutation and 1p/19q codeletion status
were observed using previously described methods [15, 16]. The institutional review board of
Yonsei University Severance Hospital approved the study protocols and the patients gave writ-
ten informed consent for participation. As controls, a total of 375 unrelated population-con-
trols (PCs), which excluded participants who had past medical history of various cancer types,
were collected from the National Biobank of Korea, the Korean Genome and Epidemiology
Study (KoGES) Consortium [17]. The PCs consisted of quality-controlled biospecimen collec-
tions from population-based cohorts which comprised 10,038 blood donors aged 40 to 60
years from the Ansung-Ansan Community-based Cohort in 2001. Genomic DNA of blood
samples was isolated using the Wizard Genomic DNA Purification Kit (Promega, Madison,
WI) for genetic analyses.
SNP selection and genotyping
The candidate RTEL1 SNPs were filtered to remove those sites with minor allele frequency
(MAF) <5% in Han Chinese Beijing and Japanese Tokyo panels from the 1000 Genomes Proj-
ect [18]. The SNPs (rs6089953, rs6010620, rs4809324, rs6062302, and rs3208008) were included
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according to previous associations with risk of gliomas [9, 10]. The final 26 SNPs in RTEL1
were selected on the basis of high linkage disequilibrium (LD) between SNPs of interest (r2
>.98). The glioma SNP rs2297440 was excluded from our study because of perfect LD (r2 = 1)
with rs6010620 in East Asian populations [18, 19]. We also included low frequency (MAF
�5%) of seven non-synonymous SNPs (rs184051277, rs199685200, rs77086616, rs199796539,
rs200933423, rs115303435, and rs115264605), except that non-synonymous SNPs were not
designable on Fluidigm SNP Type assays (Fluidigm Corp., South San Francisco, CA, US). In
addition, all loci were genotyped by the Fluidigm high-throughput platform and Fluidigm EP1
SNP Genotyping 192.24 Dynamic Array. The discrete genotype data were analyzed with the
BioMark SNP Genotyping analysis software (version 4.3.2). Among 26 RTEL1 SNPs, four
SNPs (rs184051277, rs199685200, rs199796539, and rs115264605) were monomorphic and
excluded from additional statistical analysis.
Statistics
For each SNPs, the deviation of the genotype proportions from those expected under Hardy-
Weinberg equilibrium (HWE) was examined. LD analysis between genotyped SNPs was car-
ried out using the Haploview v4.2 software from the Broad Institute (http://www.
broadinstitute.org/mpg/haploview). Haplotypes of each individual were reconstructed using
the PHASE 2.1 software [20]. Odds ratios (ORs) and corresponding P-values were calculated
using unconditional logistic regression under an additive model, adjusted for age and sex as
covariates. The significant P-values were corrected for multiple testing of 22 times using Bon-
ferroni correction. In addition, conditional logistic regression and stepwise analysis were
undertaken to identify the independence of association among the significant RTEL1 variants.
All statistical analyses were conducted using SAS 9.4 software (SAS Inc., Cary, NC, US).
Functional analysis
To predict the function of significantly associated RTEL1 SNPs with risk of glioma, in silico
analysis for non-synonymous SNPs was performed using TransFIC (http://bbglab.
irbbarcelona.org/transfic/home), which includes well-known tools (SIFT, Polyphen2, Mutatio-
nAssessor) for assessing the impact of variants in cancer. The TransFIC method normalizes
the results from the tools on a baseline tolerance of missense SNPs with dissimilar functions.
FuncPred (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html) was used to identify the tran-
scriptional regulation of significant RTEL1 SNPs.
Results
Subjects characteristics
All glioma patients composed of astrocytic and oligodendroglial tumor groups fulfilled the
inclusion criteria defined by the 2007 WHO classification [21]. The majority of gliomas (92%)
which included test results of IDH mutation and 1p/19q codeletion status were categorized as
astrocytomas, oligodendrogliomas, and GBM as defined by the 2016 CNS WHO classification
[3]. The IDH-mutants were found in 72 (29.6%) of the 243 glioma patients and the rate of gli-
oma patients with 1p/19q codeletion was 25.9% (61 of 236). Molecular alterations in GBM were
less prevalent in both IDH mutants (10.9%) and 1p/19q codeletions (11.6%). The case group
consisted of patients with 250 unrelated adult gliomas (mean age 51.13 ± 14.71, 52.4% male)
and the control group consisted of 375 individuals over 40 years old (mean age 53.61 ± 8.97,
46.9% male). The detailed histologic and acquired molecular features of cases are summarized
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in Table 1. In addition, we compare molecular characteristics of obtained IDH mutations and
1p/19q codeletions with other glioma studies (S1 Table).
Genotyping results and associations between RTEL1 SNPs and glioma risk
The genotyped SNPs’ location of RTEL1 is displayed in S1A Fig. Three LD blocks were con-
structed from the 22 RTEL1 SNPs (S1B and S2 Figs). We found that the four sets of SNPs
(rs6089953-rs3848669, rs6010620-rs3787089, rs62207047-rs4809324, and rs3208008-rs2297441)
had high LD (r2>.90). Although the genotype distributions for SNPs were in accordance with
HWE (P>.05), a novel missense variant (rs77086616, T434M) in RTEL1 was only observed in
anaplastic astrocytoma and GBM patients (HWE P = 1.55x10-16). In addition, 13 RTEL1 SNPs
were found to have significant associations with risk of adult gliomas in Korean populations
(Table 2). After applying the of Bonferroni correction (threshold P = .0023), four intronic
(rs6089953, rs3848669, rs6010620, rs3787089), one synonymous (rs6062302, D664D), and one
missense (rs115303435, A1059T) SNP were found to be significant for glioma risk.
Genetic effects of causal variants on glioma risk
To further confirm the independent association between significant SNPs and glioma risk, step-
wise and conditional logistic regression analyses were conducted on the six significant RTEL1 var-
iants. As shown in Table 3, two SNPs (rs6062302 and rs115303435) remained in the model at the
parametric discriminant P-value (0.05). After applying conditional logistic regression, the same
conclusion was independently reached, although rs6062302 showed a much weaker association
than rs115303435 after the significant RTEL1 variants were conditioned. In addition, we examined
the differential association between the two independent SNPs (rs6062302 and rs115303435) and
glioma subgroups with respect to clinical characteristics such as WHO grade, histological type,
and molecular alteration. They were found to be possibly involved with increased risk of gliomas
regardless of histologic features, IDH mutations, and 1p/19q codeletion status (Fig 1).
Assessment of the functional effects of RTEL1 variants
Our significant missense variants were evaluated via in silico analysis using the TransFIC
method. Although rs115303435 (A1059T) had low functional and structural impact on the
cancer data, rs77086616 (T434M) was observed to have medium functional impact on RTEL1
when the TransFIC method was applied with the SIFT tool. In the FuncPred method, a coding
variant rs6062302 (D664D) was predicted to alter transcription factor binding (S2 Table).
Table 1. Clinical characteristics of study subjects.




Male (%) Molecular alteration (n)




Gliomas (II - IV) 250 51.1±14.7 52.4% 72/171/7 61/175/14
Diffuse astrocytoma (II) 28 46.5±13.1 50.0% 16/12/0 6/22/0
Anaplastic astrocytoma (III) 29 41.1±14.4 48.3% 8/20/1 4/23/2
Oligodendroglioma (II) 16 46.1±7.5 50.0% 14/0/2 16/0/0
Anaplastic oligodendroglioma (III) 18 43.6±11.2 61.1% 17/0/1 18/0/0
Glioblastoma (IV) 159 55.1±14.4 52.8% 17/139/3 17/130/12
Population controls 375 53.6±9.0 46.9% - -
Abbreviation: SD, standard deviation; IDH, isocitrate dehydrogenase; NOS, not otherwise specified genetic testing of gliomas.
https://doi.org/10.1371/journal.pone.0207660.t001
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Table 2. Genotyped RTEL1 SNP information and associations of variants with risk of glioma.

















rs6089759 (T>G) 63656966 Promoter .166 .115 .135 .388 .586 .885 1.61 (1.15–2.25) .005 NS
rs6122022 (C>A) 63658242 5’UTR .078 .076 .077 .647 .111 .130 1.02 (0.65–1.58) .93 NS
rs2297432 (C>T) 63659310 5’UTR .150 .124 .134 .852 .557 .556 1.25 (0.90–1.74) .17 NS
rs6089953a (A>G) 63659655 Intron 2 .316 .240 .270 .386 .497 .951 1.52 (1.17–1.97) .001 .03
rs2738778 (C>T) 63660477 Intron 2 .454 .493 .478 .008 .500 .233 0.82 (0.66–1.04) .10 NS
rs3848669 (G>T) 63669458 Intron 8 .316 .237 .269 .386 .592 .974 1.54 (1.19–2.01) .0009 .02
rs35902944 (G>C) 63677042 Intron 10 .365 .324 .340 .415 .786 .710 1.19 (0.93–1.51) .15 NS
rs34538116 (C>T) 63677077 Intron 10 .320 .333 .328 .323 .278 .822 0.93 (0.73–1.19) .60 NS
rs2738782 (A>G) 63677217 Intron 10 .474 .451 .460 .671 .024 .136 1.11 (0.89–1.39) .33 NS
rs2738783 (G>T) 63677259 Intron 10 .408 .484 .454 .241 .933 .355 0.72 (0.57–0.90) .005 NS
rs6010620a (A>G) 63678486 Intron 11 .320 .241 .273 .642 .964 .918 1.55 (1.19–2.01) .0009 .02
rs62207047 (C>T) 63679610 Intron 11 .126 .079 .098 .578 .628 .983 1.77 (1.20–2.59) .003 NS
rs3787089 (G>A) 63685277 Intron 13 .314 .239 .269 .284 .918 .520 1.55 (1.19–2.02) .001 .02
rs77086616 (C>T) 63685825 Exon 15 (T434M) .012 .000 .005 2.71x10-7 - 1.55x10-16 - .01c -
rs4809324a (T>C) 63686867 Intron 15 .127 .081 .099 .572 .720 .943 1.72 (1.17–2.51) .005 NS
rs79210260 (C>T) 63689576 Exon 22 (R651R) .100 .101 .101 .702 .223 .234 1.01 (0.69–1.47) .94 NS
rs6062302a (T>C) 63689615 Exon 22 (D664D) .349 .253 .290 .787 .561 .621 1.62 (1.26–2.10) .0002 .004
rs200933423 (C>G) 63694443 Exon 30 (L1022V) .012 .007 .009 .848 .897 .824 1.99 (0.59–6.67) .26 NS
rs3208008a (A>C) 63694757 Exon 31 (Q1042H) .369 .308 .333 .174 .918 .471 1.37 (1.07–1.76) .01 NS
rs115303435a (G>A) 63694806 Exon 31 (A1059T) .066 .027 .042 .264 .596 .268 3.06 (1.69–5.54) .0002 .003
rs41309931 (G>T) 63695226 Intron 33 .192 .147 .165 .620 .700 .994 1.41 (1.04–1.91) .03 NS
rs2297441 (G>A) 63696229 3’UTR .353 .295 .318 .255 .913 .562 1.36 (1.06–1.74) .01 NS
Logistic regression analysis under additive model was used for calculating ORs and corresponding P-values for SNPs controlling age and sex as covariates.
Significant associations are shown in bold face.
aSNPs were analyzed in previous studies on glioma risk.
bBonferroni-adjusted P-values by 22 SNP tests.
cThe P-value was determined using the χ2 test because no variants were observed in PCs.
Abbreviation: Chr., chromosome; PC, population control; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; NS, not significant.
https://doi.org/10.1371/journal.pone.0207660.t002
Table 3. Independent association signals among glioma-associated RTEL1 variants.
SNP P Stepwise Pa Conditional P-value by
rs6089953b rs3848669 rs6010620b rs3787089 rs6062302b rs115303435
rs6089953b .001 - - .93 .83 .58 .78 .03
rs3848669 .0009 - .93 - .59 .40 .93 .02
rs6010620b .0009 - .41 .63 - .48 .45 .02
rs3787089 .001 - .50 .70 .95 - .19 .03
rs6062302b .0002 .0004 .05 .07 .05 .02 - .004
rs115303435 .0002 .01 .006 .007 .006 .007 .01 -
The P-values were obtained by logistic analysis between glioma patients (n = 250) and PCs (n = 375) under additive model.
Significant associations are shown in bold face.
aThe significance level was set at 0.05 in stepwise selection of glioma-associated RTEL1 SNPs.
bPreviously identified loci in RTEL1.
https://doi.org/10.1371/journal.pone.0207660.t003
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Discussion
This study demonstrates that previously identified loci in RTEL1 are confirmed to have an
association with increased risk of adult gliomas. Moreover, two coding variants (rs6062302
and rs115303435) were found to confer independent risk for glioma in RTEL1. A novel mis-
sense SNP (rs77086616, T434M) was also observed only in Korean glioma samples. In addi-
tion, we compared the associations between causal RTEL1 markers and glioma subgroups
based on grades of malignancy and histopathological subtypes.
A number of GWASs and candidate gene studies have identified RTEL1 variants involved
with genetic predispositions to glioma development [6, 7, 22]. A summary of studies between
RTEL1 variants and glioma risk is listed in S3 Table. Of the extensively investigated RTEL1
SNPs, the intronic rs6010620 was the most studied SNP in White and Chinese populations,
although there were differences in the effect of this SNP on glioma risk [12]. Recently, the
GWAS meta-analyses in up to 30,686 individuals showed that the significant association at
RTEL1 rs2297440 was observed between the risk of GBM and non-GBM tumors [7]. However,
we did not find any association of the RTEL1 variants from the case-only analysis (rs2297440
was replaced by rs6010620 with LD in East Asian populations).
In case-control studies, rs6010620 and rs2297440 were found to be associated with glioma
development [11] and GBM risk [23] in Han Chinese populations. The intronic rs6010620 and
rs4809324 were independent predictors of glioma risk in European ancestry individuals [9],
whereas the risk of glioma development [11] and GBM [23] in Han Chinese was not influ-
enced by rs4809324. rs6010620, rs2297440, and rs4809324 were presented in one haplotype
block which was associated with increased risk of astrocytoma in Chinese populations [24].
Unconditional logistic regression analysis showed that rs6010620 and rs4809324 were associ-
ated with increased risk of adult glioma in Korean populations (Table 2). The resulting LD
between rs6010620 and rs4809324 was high (r2 = .94, S2 Fig).
Fig 1. The association results of two independent SNPs between glioma subgroups and PCs. Logistic regression
between glioma subgroups and PCs (n = 375) under additive model, adjusted by age and sex as covariates, was used for
calculating ORs (95% CI) and P-values at rs6062302 (black round) and rs115303435 (black rhombus). The each plot
indicates the point estimate of ORs on the x-axis shown with 95% CI on the error bars. Significant associations are
bolded. Abbreviations: PC, population control; WHO, world health organization grade; AST, astrocytomas, ODG,
oligodendrogliomas; GBM, glioblastomas; IDH-mutant, IDH1 or IDH2-mutated gliomas; IDH-wildtype, IDH-
wildtype gliomas; (-) 1p/19q, 1p/19q codeletion; (+) 1p19q, 1p/19q non-codeletion; OR, odds ratio; CI, confidence
interval.
https://doi.org/10.1371/journal.pone.0207660.g001
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In addition to intronic SNPs, the associations between the coding variants (rs6062302 and
rs3208008) and risk of adult gliomas were observed in US population study [10], a fact which
was replicated in this study (S3 Table). An exome-wide association study has also identified a
number of missense SNPs in RTEL1, including rs3208008 (Q1042H) and rs115303435
(A1059T), in a Han Chinese population, although rs115303435 showed marginal association
with GBM risk after conditional analysis by rs6010620 (P = .059) [25]. Among those glioma-
associated SNPs, rs6062302 and rs115303435 were replicated in our Korean subjects as causal
SNPs associated with increased risk of adult gliomas (Table 3). In addition, the new glioma-
specific variant (rs77086616, T434M) was identified only in certain cases and was found to be
rare (MAF = .005) in this study. More than half of the low-frequency missense alleles were
found to have deleterious effects with respect to the intensity of selective pressure among dis-
ease alleles [26]. Although rs115303435 and rs77086616 were only observed in this study and
in East Asian populations [18], to date, little information has been confirmed between a popu-
lation-specific variant and glioma risk.
Human RTEL1 is an essential DNA helicase which helps maintain genome stability through
telomere maintenance and DNA repair [27]. However, few functional studies on RTEL1 with
respect to glioma tumorigenesis have been conducted [22]. As such, it is difficult to assess the
role of oncogenic or tumor suppressor pathways. Using in silico analysis, the splicing effect of
rs6062302 was studied (S2 Table). A rare variant (rs77086616, T434M) was found to have a
medium impact on the RTEL1 function when the TransFIC method was applied. In addition,
to identify the significant SNPs that alter the expression level of RTEL1 in brain tissues, we
searched for expression quantitative trait locus data (eQTL) from the UK Brain Expression
Consosium (Braineac; http://www.braineac.org). Healthy individuals of Western European
descent with the rs6062302 C>T allele showed increased mRNA expression levels in the tem-
poral and frontal cortex compared to other brain regions. However, rs77086616 and
rs115303435 data were not available in the public eQTL database.
Recent advances in molecular profiling have contributed to understanding the molecular
aberrations of diffuse gliomas in adults [28]. IDH mutations, most of the R132 codon of IDH1,
are found frequently in a majority of astrocytomas and oligodendrogliomas cases [16]. The
combined chromosome imbalances of 1p and 19q resulting in loss of heterozygosity are prog-
nostic biomarkers for oligodendroglial tumors [15]. Likewise, our oligodendrogliomas were
shared in almost all cases with both IDH mutations and 1p/19q codeletion (Table 1). Among
the associated inherited risk variants, RTEL1 variants were found to be associated with risk of
glioma regardless of molecular alterations [6, 14]. The similar pattern was observed for our
causal variants with glioma, stratified by 2016 CNS WHO, morphology, IDH mutations, and
1p/19q codeletion (Fig 1). In particular, rs6062302 and rs115303435 were more significantly
associated with IDH-wildtype gliomas than with IDH mutants. The ORs of rs115303435 were
higher than rs6062302 in all glioma classes. However, the subgroup analyses were limited in
their statistical power due to small number of cases analyzed; these results should be inter-
preted with caution. In addition, we used general PCs matched for age and sex to estimate the
impact of the association between RTEL1 variants and risk of adult gliomas. Although popula-
tion-based controls lack clinical information for detailed inclusion and exclusion criteria, the
use of PCs in this study may be considered as an alternative method for assessing genetic
effects [29].
Despite these limitations, the present study reinforces understanding of RTEL1 association
with adult gliomas in Korean populations. Future studies considering our findings in larger
glioma samples with molecular alterations must test the reproducible markers for understand-
ing of glioma pathogenesis.
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Supporting information
S1 Table. Comparisons of IDH mutations and 1p/19q co-deletion status in each study
group. Abbreviation: US indicates United States; GBM, glioblastoma.
(DOCX)
S2 Table. In silico analysis of RTEL1 rs6062302 (D664D). In silico analysis was conducted
using FuncPred (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html). Lowercase alleles in
motif (forward strand) indicate the rs6062302 position. Threshold score for associated splicing
factor SF2 /ASF was 1.956. Abbreviation: ESE, exonic splicing enhancer; ESS, exonic splicing
silencer.
(DOCX)
S3 Table. The Studies between RTEL1 variants and glioma risk. Significant associations are
shown in bold face. Abbreviation: OR (95% CI), odds ratio (95% confidence interval); NA, not
available. �Causal SNPs on glioma risk in present study §Protective allele
(DOCX)
S1 Fig. The gene map of RTEL1 (NM_032957.4) on chromosome 20q13.33 (38.444 kb). (A)
A map of RTEL1. Coding exons are marked by black blocks, and 5’- and 3’-untranslated
regions by white blocks. (B) Haplotypes of RTEL1. The BL1_ht4 (OR = 1.67, P = .003),
BL2_ht1 (OR = 0.70, P = .003), BL2_ht4 (OR = 1.86, P = .002), BL3_ht1 (OR = 1.40, P = .007),
and BL3_ht2 (OR = 1.67, P = .03) were associated with risk of adult gliomas. Abbreviation: ht,
haplotype; PC, population control.
(TIF)
S2 Fig. The LD structure of genotyped RTEL1 SNPs. The region includes three LD blocks
marked by triangles with black lines. The SNPs in the haplotype blocks are shown in bold.
Numbers and grayscale shades in boxes indicate r2 values.
(TIF)
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